# TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct06802081` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06802081](<https://clinicaltrials.gov/study/NCT06802081>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06802081

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06802081. Randomized; triple masking; primary purpose treatment. Start 2025-04-08 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06802081, source copy `cardio:ctgov-nct06802081-2026-01-13`, retrieved 2026-10-26)
- Started: 2025-04-08 (actual) (ClinicalTrials.gov record NCT06802081, source copy `cardio:ctgov-nct06802081-2026-01-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06802081, source copy `cardio:ctgov-nct06802081-2026-01-13`, retrieved 2026-10-26)
- Completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT06802081, source copy `cardio:ctgov-nct06802081-2026-01-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06802081, source copy `cardio:ctgov-nct06802081-2026-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06802081-2026-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
- Acronym: TIRO-AF
- Condition: Atrial Fibrillation
- Condition: Obesity
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Placebo
- Lead sponsor: The Cleveland Clinic
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)

## Provenance

Content hash: 2cd7a4b5fceb76ff8a6d5374d140b63ede65203226cab2859c41e6a2d07a50c1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
